Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

EC approves Astellas' PADCEV (enfortumab vedotin) plus Merck & Co.'s Keytruda as first perioperative option for cisplatin-ineligible resectable muscle-invasive bladder cancer based on Ph3 results
Antibody-drug conjugate, cancer, bladder cancer, combination therapy, pembrolizumab, perioperative treatment - Read more

Flagship Pioneering, Lean Business Services collaborate to advance AI-enabled biomedical research and healthcare innovation in Saudi Arabia
Research collaboration, AI/ML, digital health, data analytics, drug discovery - Read more

Abbott, ALZpath ink deal to develop pTau217 blood-based Alzheimer's in vitro diagnostic test
Licensing deal, neurological, diagnostics, antibody - Read more

Novartis pays Antares Therapeutics $105M upfront to drug undruggable oncology targets, $1.8B potential
Licensing deal, oncology, small molecule, drug discovery, milestone payments, royalties - Read more

Eli Lilly expands partnership with Abbisko Therapeutics on precision oncology therapies, deal worth up to $1.9B
Licensing deal, small molecule, immuno-oncology, milestone payments, royalties - Read more

Combotope Therapeutics, Boehringer Ingelheim collaborate on tumor-selective antibody therapies for cancer, financial terms undisclosed
Research collaboration, oncology, antibody, drug discovery, milestone payments, royalties - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Osanni Bio raises $190M Series B to advance ophthalmology, cardiology, and cancer pipeline
Ophthalmology, oncology, cardiovascular, clinical-stage, platform-enabled - Read more

RQ Biotechnology raises $115M Series A to advance flu preventative antibody program
Infectious disease, antibody, respiratory, influenza, preclinical - Read more

Ollin Biosciences raises $330M Series B to advance Vabysmo-challenging eye disease therapy
Ophthalmology, antibody, wet AMD, clinical-stage - Read more

MoonLake Immunotherapeutics prices upsized $200M public offering, advancing sonelokimab for inflammatory diseases
Clinical-stage, autoimmune, inflammatory disease, antibody - Read more

Definium Therapeutics prices upsized $700M public offering, advancing psychiatric and neurological disorder treatments
Neurological, psychiatric disorders, small molecule, clinical-stage - Read more

uniQure prices upsized $225M public offering, advancing gene therapies for severe diseases
Gene therapy, rare disease, clinical-stage - Read more

LyncBio Therapeutics secures ~100M RMB ($12.93M) Pre-A+ funding to advance IBD and oncology ADC platforms
Antibody-drug conjugate, autoimmune, oncology, IBD, clinical-stage - Read more

Rapalogix Health raises $20M Series A, advancing longevity-based skin health and dermatological solutions
Dermatology, longevity, small molecule, skincare, preclinical - Read more

NorthLinks Bio secures $34M funding to advance intranasal antiviral prophylactic toward Phase 2b
Infectious disease, antiviral, intranasal delivery, clinical-stage, platform technology - Read more

AdvanCell secures 128,000-sq-ft Boston-area lease for U.S. headquarters and radiopharmaceutical manufacturing
Radiopharmaceutical, oncology, operational, strategic - Read more

Incyte settles CMS lawsuit, wins Opzelura reclassification, securing $246M Q2 benefit
Small molecule, dermatology, regulatory, financial - Read more

Serapha Bio goes public via reverse merger with Boundless Bio, raising $230M and licensing gene editor from China
Gene editing, rare disease, major transaction, financial - Read more

Takeda enters transitional FY26 under new CEO Julie Kim, targeting growth via three pipeline launches
Small molecule, narcolepsy, strategic, financial, cost reduction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

ADC Therapeutics cuts 17% of staff amid Zynlonta safety concerns, targeting $10M annual savings
Antibody-drug conjugate, oncology, cost reduction, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here